Anthony Principi - Imprimis Pharmaceuticals Independent Director
Director
Mr. Anthony J. Principi is Independent Director of Imprimis Pharmaceuticals, Inc. Mr. Principi served as Secretary, and during his tenure was responsible for a nationwide system of health care services, benefits programs and national cemeteries for America 25 million veterans and dependents. Mr. Principi serves as CEO and president of The Principi Group, LLC, a consulting firm. In 2007, Mr. Principi joined the Wounded Warrior Project and was appointed to the position of Vice President in 2011 and served on the board until 2014. From 2005 through 2010, he was the Senior Vice President of Government Relations of Pfizer, Inc. Prior to joining Pfizer, Inc., Mr. Principi served as Secretary of the U.S. Department of Veterans Affairs from 2001 through 2005. In 2005, he served as the Chairman of the Defense 2005 Base Realignment and Closure Commission. Prior to becoming Secretary of the U.S. Department of Veterans Affairs, Mr. Principi was President of QTC Medical Services Inc. from 1999 through 2001 and Senior Vice President of Lockheed Martin IMS from 1995 through 1996. Prior to joining Lockheed Martin IMS, Mr. Principi was Chief Counsel and Staff Director of the U.S. Senate Armed Services Committee from 1993 through 1994, and was Chief Counsel and Staff Director of the U.S. Senate Committee on Veterans Affairs from 1984 through 1988. Mr. Principi serves as a director of Mutual of Omaha. He is also a member of the board of directors of Engility Holdings, Inc., GetWellNetwork, Inc. and Cleveland BioLabs, Inc. Mr. Principi served as Executive Chairman of QTC Management, and was a Director of Perot Systems Corporation since 2015.
| Age | 72 |
| Tenure | 9 years |
| Phone | 858-704-4040 |
| Web | http://www.imprimisrx.com |
Imprimis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (11.94) % which means that it has lost $11.94 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (153.09) %, meaning that it created substantial loss on money invested by shareholders. Imprimis Pharmaceuticals' management efficiency ratios could be used to measure how well Imprimis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 15.28 M in liabilities with Debt to Equity (D/E) ratio of 343.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Imprimis Pharmaceuticals has a current ratio of 1.11, suggesting that it may not be capable to disburse its financial obligations when due. Debt can assist Imprimis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Imprimis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Imprimis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Imprimis to invest in growth at high rates of return. When we think about Imprimis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Evans | Barrick Gold Corp | 60 | |
| Gustavo Cisneros | Barrick Gold Corp | 74 | |
| Pablo Marcet | Barrick Gold Corp | 53 | |
| Brian Greenspun | Barrick Gold Corp | 73 | |
| Norborne Cole | Barrick Gold Corp | 73 | |
| Susan Ellerbusch | Summit Materials | 53 | |
| Graham Clow | Barrick Gold Corp | 66 | |
| Olivia Kirtley | Barrick Gold Corp | 66 | |
| Anne Cooney | Summit Materials | 61 | |
| Anne Wade | Summit Materials | 48 | |
| Steven Shapiro | Barrick Gold Corp | 65 | |
| Joseph Cantie | Summit Materials | 57 | |
| Robert Prichard | Barrick Gold Corp | 68 | |
| Kadri Dagdelen | Barrick Gold Corp | 60 | |
| Steven Wunning | Summit Materials | 70 | |
| John Murphy | Summit Materials | 70 | |
| Loreto Silva | Barrick Gold Corp | 55 | |
| Karl Voltaire | Barrick Gold Corp | 63 | |
| Safiatou BaNDaw | Barrick Gold Corp | 64 | |
| Ernie Thrasher | Barrick Gold Corp | 61 | |
| Julia Kahr | Summit Materials | 37 | |
Management Performance
| Return On Equity | -153.09 | |||
| Return On Asset | -11.94 |
Imprimis Pharmaceuticals Leadership Team
Elected by the shareholders, the Imprimis Pharmaceuticals' board of directors comprises two types of representatives: Imprimis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imprimis. The board's role is to monitor Imprimis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Imprimis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imprimis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Nelson, Director | ||
| Robert Kammer, Chairman of the Board | ||
| Clayton Edwards, COO | ||
| John Saharek, Chief Commercial Officer | ||
| Anthony Principi, Independent Director | ||
| Andrew Boll, Vice President - Accounting and Financial Reporting | ||
| Mark Baum, CEO, Director | ||
| Richard Lindstrom, Director | ||
| Stephen Austin, Independent Director |
Imprimis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Imprimis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -153.09 | |||
| Return On Asset | -11.94 | |||
| Profit Margin | (16.81) % | |||
| Operating Margin | (13.94) % | |||
| Current Valuation | 120.54 M | |||
| Shares Outstanding | 23.28 M | |||
| Shares Owned By Insiders | 7.16 % | |||
| Shares Owned By Institutions | 23.26 % | |||
| Number Of Shares Shorted | 231.01 K | |||
| Price To Earning | (2.02) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Imprimis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Imprimis Pharmaceuticals' short interest history, or implied volatility extrapolated from Imprimis Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Imprimis Stock
If you are still planning to invest in Imprimis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imprimis Pharmaceuticals' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |